good shepherd physical therapy, pLLC

600 w 190 street
apt. 2a
new york, new york 10040

NYS Entity Status
ACTIVE

NYS Filing Date
JANUARY 15, 2014

NYS DOS ID#
4514184

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC PROFESSIONAL SERVICE LIMITED LIABILITY COMPANY

Name History
2014 - GOOD SHEPHERD PHYSICAL THERAPY, PLLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York
  • How Sister Paulette LoMonaco Spends Her Sundays
    By JOHN LELAND - Friday May 12, 2017

    The executive director of the nonprofit Good Shepherd Services spends much of the day in prayer, and on the golf course.

    Source: New York Times
  • Inside New York City’s Priciest Rentals
    By CAROLINE BIGGS - Friday Sep 1, 2017

    Some New Yorkers could afford to buy multimillion-dollar properties, but they’d rather rent a place for upward of $20,000 a month.

    Source: NYT > Home Page
  • FDA Clears Way for Filing on Psych Drug From Intra-Cellular, Shares Climb
    By Ben Fidler - Wednesday Aug 23, 2017

    The FDA has just lowered a key barrier standing between Intra-Cellular Therapies and potential approval of an experimental schizophrenia drug. Now the question is whether the mixed set of data the company has accrued to support the program will be good enough for regulators. Intra-Cellular (NASDAQ: ITCI) said the FDA has finished looking over responses […]

    Source: Xconomy New York
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York